Integrating chemokine signatures and multi-omic biomarkers to predict immunotherapy response in non-small cell lung cancer: a comprehensive narrative review

作者：Cabezón-Gutiérrez L, Palka-Kotlowska M, Custodio-Cabello S, Rosero-Rodriguez AC, Chacón-Ovejero B · 发表于：Frontiers in oncology · 年份：2026 · DOI：10.3389/fonc.2026.1830731 · 被引用次数：109

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have revolutionized the therapeutic landscape, only 20-30% of unselected patients achieve durable clinical benefits. Given the imperfect predictive value of traditional markers, such as PD-L1 expression and tumor mutational burden, there is an urgent need for multidimensional biomarkers to guide personalized immunotherapy. This review evaluates emerging predictive tools, with a specific focus on chemokine signatures and multi-omic (genomic, transcriptomic, proteomic, and metabolomic) biomarkers, including integrative models. By examining the biological rationale linking tumor microenvironment chemokine networks to antitumor immunity, we discuss recent advances in profiling that enable comprehensive predictive signatures. A comprehensive narrative literature search of PubMed and EMBASE (2015-2026) was performed to identify relevant peer-reviewed studies, clinical trials, and computational analyses. Evidence suggests that integrating chemokine profiles with multi-omic data holds significant promise for improving patient selection. Multidimensional models incorporating tumor genomics and immune microenvironment features are likely to outperform single-analyte tests in identifying ICI responders. Despite ongoing challenges, such as tumor heterogeneity, assay standardization, and data integration complexity, the de...